Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;10(2):147–166. doi: 10.1111/j.1527-3458.2004.tb00010.x

TC‐1734: An Orally Active Neuronal Nicotinic Acetylcholine Receptor Modulator with Antidepressant, Neuroprotective and Long‐Lasting Cognitive Effects

Gregory J Gatto 1, G Andrees Bohme 2, William S Caldwell 1, Sharon R Letchworth 1, Vincent M Traina 1, M Carmen Obinu 2, Michel Laville 2, Michel Reibaud 2, Laurent Pradier 2, Geoffrey Dunbar 1, Merouane Bencherif 1,✉
PMCID: PMC6741718  PMID: 15179444

ABSTRACT

The development of selective ligands targeting neuronal nicotinic acetylcholine receptors to alleviate symptoms associated with neurodegenerative diseases presents the advantage of affecting multiple deficits that are the hallmarks of these pathologies. TC‐1734 is an orally active novel neuronal nicotinic agonist with high selectivity for neuronal nicotinic receptors. Microdialysis studies indicate that TC‐1734 enhances the release of acetylcholine from the cortex. TC‐1734, by either acute or repeated administration, exhibits memory enhancing properties in rats and mice and is neuroprotective following excitotoxic insult in fetal rat brain in cultures and against alterations of synaptic transmission induced by deprivation of glucose and oxygen in hippocampal slices. At submaximal doses, TC‐1734 produced additive cognitive effects when used in combination with tacrine or donepezil. Unlike (‐)‐nicotine, behavioral sensitization does not develop following repeated administration of TC‐1734. Its pharmacokinetic (PK) profile (half‐life of 2 h) contrasts with the long lasting improvement in working memory (18 h) demonstrating that cognitive improvement extends beyond the lifetime of the compound. The very low acute toxicity of TC‐1734 and its receptor activity profile provides additional mechanistic basis for its suggested potential as a clinical candidate. TC‐1734 was very well tolerated in acute and chronic oral toxicity studies in mice, rats and dogs. Phase I clinical trials demonstrated TC‐1734's favorable pharmacokinetic and safety profile by acute oral administration at doses ranging from 2 to 320 mg.

The bioavailability, pharmacological, pharmacokinetic, and safety profile of TC‐1734 provides an example of a safe, potent and efficacious neuronal nicotinic modulator that holds promise for the management of the hallmark symptomatologies observed in dementia.

Keywords: Acetylcholinesterase inhibitors, Alzheimer's disease, CNS selectivity, Neuronal nicotinic acetylcholine receptors

Full Text

The Full Text of this article is available as a PDF (268.5 KB).

REFERENCES

  • 1. Akaike A, Tamura Y, Yokaota T, Shimohama, S , Kimura J. Nicotine induce protection of cultured cortical neurones against N‐methyl‐D‐aspartate receptor‐mediated glutamate cytotoxicity. Brain Res 1994;644:181–187. [DOI] [PubMed] [Google Scholar]
  • 2. Arendash GW, Sanberg PR, Sengstock GJ. Nicotine enhances the learning and memory of aged rats. Pharmacol Biochem Behav 1995;52:517–523. [DOI] [PubMed] [Google Scholar]
  • 3. Arneric, SP , Sullivan JP, Briggs CA, et al. Preclinical pharmacology of ABT‐418: A prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease. CNS Drug Rev 1995;1:1–26. [Google Scholar]
  • 4. Bannon AW, Decker MW, Curzon P, et al. ABT‐594 [(R)‐5‐(2‐azetidinylmethoxy)‐2‐chloropyridine]: A novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther 1998;285:787–794. [PubMed] [Google Scholar]
  • 5. Bencherif M. Pharmaceutical compositions for the prevention and treatment of central nervous disorders. US Pat. No. 6,218,383; 2001.
  • 6. Bencherif M, Bane AJ, Miller CH, Dull GM, Gatto GJ. TC‐2559: A novel orally active ligand selective at neuronal acetylcholine receptors. Eur J Pharmacol 2000;409:45–55. [DOI] [PubMed] [Google Scholar]
  • 7. Bencherif M, Lovette ME, Fowler KW, et al. TC‐2403: A nicotinic agonist with CNS selectivity. I. In vitro characterization. J Pharmacol Exp Ther 1996;279:1413–1421. [PubMed] [Google Scholar]
  • 8. Bencherif M, Schmitt JD. Targeting neuronal nicotinic receptors: A path to new therapies. Curr Drug Target CNS Neurol Disord 2002;1:349–357. [DOI] [PubMed] [Google Scholar]
  • 9. Bontempi B, Whelan KT, Risbrough VB, et al. SIB‐1553A, (‐)‐4‐[[2‐(1‐methyl‐2‐pyrrolidinyl)ethyl]‐thio]phenol hydrochloride, a subtype‐selective ligand for nicotinic acetylcholine receptors with putative cognitive‐enhancing properties: Effects on working and reference memory performances in aged rodents and nonhuman primates. J Pharmacol Exp Ther 2001;299:297–306. [PubMed] [Google Scholar]
  • 10. Borlongan CV, Shytle RD, Ross SD, et al. (–)‐Nicotine protects against systemic kainic acid‐induced excito‐toxic effects. Exp Neurol 1995;136:261–265. [DOI] [PubMed] [Google Scholar]
  • 11. Brioni JD, Decker MW, Sullivan JP, Arneric SP. The pharmacology of (–)‐nicotine and novel cholinergic channel modulators In: August JT, Anders MW, Murad F, Coyle JT, Eds. Advances in pharmacology. New York : Academic Press, 1997;153–214. [DOI] [PubMed] [Google Scholar]
  • 12. Buccafusco JJ, Terry AV. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 2000;295:438–446. [PubMed] [Google Scholar]
  • 13. Cosford NDP, Bleitcher L, Herbaut A, et al. (S)‐(–)‐5‐Ethynyl‐3‐(1‐methyl‐2‐pyrrolidinyl)pyridine maleate (SIB‐1508Y): A novel anti‐parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem 1996;39:3235–3237. [DOI] [PubMed] [Google Scholar]
  • 14. Decker MW, Brioni JD, Sullivan JP, et al. (S)‐3‐Methyl‐5‐(1‐methyl‐2‐pyrrolidinyl)isoxazole (ABT‐418): A novel cholinergic ligand with cognition‐enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther 1994;270:319–328. [PubMed] [Google Scholar]
  • 15. Donnelly‐Roberts DL, Xue IC, Arneric SP, Sullivan, JP . In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT‐418. Brain Res 1996;719:36–44. [DOI] [PubMed] [Google Scholar]
  • 16. Janson AM, Hedlund PB, Fuxe K, von Euler G. Chronic nicotine treatment counteracts dopamine D2 receptor upregulation induced by a partial meso‐diencephalic hemitransection in the rat. Brain Res 1994;655:25–32. [DOI] [PubMed] [Google Scholar]
  • 17. Jeyarasasingam G, Tompkins L, Quik M. Stimulation of non‐alpha7 nicotinic receptors partially protects dopaminergic neurons from 1‐methyl‐4‐phenylpyridinium‐induced toxicity in culture. Neuroscience 2002;109:275–285. [DOI] [PubMed] [Google Scholar]
  • 18. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing, and short‐term memory in Alzheimer's disease. Psychopharmacology 1992;108:485–494. [DOI] [PubMed] [Google Scholar]
  • 19. Kaneko S, Maeda T, Kume T, et al. Nicotine protects cultured cortical neurons against glutamate‐induced cytotoxicity via alpha7‐neuronal receptors and neuronal CNS receptors. J Brain Res 1997;765:135–140. [DOI] [PubMed] [Google Scholar]
  • 20. Kihara T, Shimohama S, Sawada H, et al. Nicotinic receptor stimulation protects neurons against beta‐amyloid toxicity. Ann Neurol 1997;42:59–63. [DOI] [PubMed] [Google Scholar]
  • 21. Kihara T, Shimohama S, Urushitani M, et al. Stimulation of α4β2 nicotinic acetylcholine receptor inhibits β‐amyloid toxicity. Brain Res 1998;792:331–334. [DOI] [PubMed] [Google Scholar]
  • 22. Levin ED, Nicotinic system and cognitive function. Psychopharmacology 1992;108:485–494. [DOI] [PubMed] [Google Scholar]
  • 23. Levin ED, Briggs SJ, Christopher NC. Persistence of chronic‐induced cognitive facilitation. Behav Neural Biol 1992;58:152–158. [DOI] [PubMed] [Google Scholar]
  • 24. Levin ED, Briggs SJ, Christopher NC, Rose JE. Chronic stimulation and blockade effects on working memory. Behav Pharmacol 1993;4:179–182. [PubMed] [Google Scholar]
  • 25. Lippiello PM, Bencherif M, Gray JA, et al. TC‐2403: A nicotinic agonist with CNS selectivity. I. In vivo characterization. J Pharmacol Exp Ther 1996;279:1422–1429. [PubMed] [Google Scholar]
  • 26. Lippiello PM, Gatto G, Bencherif M, Caldwell WS. TC‐1734: A potent selective nicotinic ligand improves cognition acutely and chronically. Abstr Soc Neurosci 1998;24:88. [Google Scholar]
  • 27. Marin P, Maus M, Desagher S, Glowinsky J, Premont J. Nicotine protects cultured striatal neurons against N‐methyl‐D‐aspartate receptor‐mediated neurotoxicity. Neuroreport 1994;5:1977–1980. [DOI] [PubMed] [Google Scholar]
  • 28. Nanri M, Kasahara N, Yamamoto J, Miyake H, Watanabe H. GTS‐21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats. Jpn J Pharmacol 1997;74:285–289. [DOI] [PubMed] [Google Scholar]
  • 29. Newhouse PA, Sunderland T, Thompson K, et al. Intravenous nicotine in a patient with Alzheimer's disease. Am J Psychiatry 1986;143:1494–1495. [DOI] [PubMed] [Google Scholar]
  • 30. Obinu MC, Reibaud M, Miquet JM, Pasquet M, Rooney T. Brain‐selective stimulation of nicotinic receptors by TC‐1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog Neuropsy-chopharmacol Biol Psychiatry 2002;26:913–918. [DOI] [PubMed] [Google Scholar]
  • 31. Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short‐term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 1989;154:797–800. [DOI] [PubMed] [Google Scholar]
  • 32. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. Nicotine inhibits amyloid formation by the beta‐peptide. Biochemistry 1996;35:13568–13578. [DOI] [PubMed] [Google Scholar]
  • 33. Schmitt JD, Bencherif M. Targeting nicotinic acetylcholine receptors: Advances in molecular design and therapies In: Doherty AM, Ed. Annual report in medicinal chemistry. San Diego : Academic Press, 2000;41–51. [Google Scholar]
  • 34. Semba J, Miyoshi R, Kito S. Nicotine protects against the dexamethasone potentiation of kainic acid‐induced neurotoxicity in cultured hippocampal neurons. Brain Res 1996;735:335–338. [DOI] [PubMed] [Google Scholar]
  • 35. Shaw S. M. Bencherif, Marrero MB. Janus kinase 2: An early target of alpha7 nicotinic acetylcholine receptor mediated neuroprotection against Aβ(1–42). J Biol Chem 2002;277:44920–44924. [DOI] [PubMed] [Google Scholar]
  • 36. Shimohama S, Akaike A, Kimura J. Nicotine‐induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor‐mediated inhibition of nitric oxide formation. Ann NY Acad Sci 1996;77:356–361. [DOI] [PubMed] [Google Scholar]
  • 37. Summers KL, Giacobini E. Effects of local and repeated systemic administration of (–)nicotine on extracellular levels of acetylcholine, norepinephrine, dopamine, and serotonin in rat cortex. Neurochem Res 1995;20:683–689. [DOI] [PubMed] [Google Scholar]
  • 38. Summers KL, Lippiello P, Giacobini E. A microdialy sis study of the effects of the nicotinic agonist TC‐2403 on cortical release of acetylcholine andbiogenic amines. Neurochem Res 1996;21:1181–1186. [DOI] [PubMed] [Google Scholar]
  • 39. Yamashita H, Nakamura S. Nicotine rescues PC 12 cells from death induced by nerve growth factor deprivation. Neurosci Lett 1996;213(2):145–147. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES